An open-label, dose-titration, long-term safety study to evaluate Concerta (methylphenidate HCL [hydrochloride]) extended-release tablets at doses of 36 mg, 54 mg, 72 mg, 90 mg, and 108 mg per day in adults with attention deficit hyperactivity disorder

Trial Profile

An open-label, dose-titration, long-term safety study to evaluate Concerta (methylphenidate HCL [hydrochloride]) extended-release tablets at doses of 36 mg, 54 mg, 72 mg, 90 mg, and 108 mg per day in adults with attention deficit hyperactivity disorder

Completed
Phase of Trial: Phase III

Latest Information Update: 04 May 2010

At a glance

  • Drugs Methylphenidate (Primary)
  • Indications Attention-deficit hyperactivity disorder
  • Focus Adverse reactions
  • Sponsors McNeil-PPC
  • Most Recent Events

    • 20 Nov 2008 Planned number of patients changed from 450 to 560.
    • 07 Feb 2008 Status changed from in progress to completed according to ClinicalTrials.gov
    • 25 Jun 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top